Physician profile
Perry B Sheidayi
NPI 1508823519
$8,456.12
in general payments reported to CMS, 2019-2025
29 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $374 · 2021: $647 · 2022: $1,390 · 2023: $1,969 · 2024: $2,168 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,709.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,122.39 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $882.45 | 2021-2025 | Mounjaro, Trulicity |
| Amgen INC. | $792.95 | 2023-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $542.65 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $434.18 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Idorsia Pharmaceuticals US INC | $301.20 | 2023-2025 | Quviviq, Quviviq |
| Glaxosmithkline, LLC. | $216.14 | 2022 | |
| Corcept Therapeutics | $148.10 | 2024 | Korlym |
| Novo Nordisk INC | $133.63 | 2021-2025 | Ozempic, Rybelsus |
| Vifor Pharma, INC. | $121.18 | 2019 | |
| Exact Sciences Corporation | $100.97 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $99.02 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $89.59 | 2022 | |
| Amarin Pharma, INC. | $73.36 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.57 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $36.56 | 2022-2023 | Accrufer |
| Novartis Pharmaceuticals Corporation | $34.96 | 2023 | |
| Insmed, INC. | $34.49 | 2023 | Arikayce |
| Biomerieux INC | $34.00 | 2025 | Biofire Spotfire Control Station |
| Neuronetics, INC. | $29.18 | 2024 | Neurostar Tms Therapy System |
| Alnylam Pharmaceuticals INC. | $25.90 | 2024 | Amvuttra |
| Genentech USA, INC. | $24.54 | 2020 | |
| Esperion Therapeutics, INC. | $24.14 | 2025 | Nexletol |
| Scilex Pharmaceuticals INC. | $21.72 | 2019 | |
| Abbvie INC. | $20.47 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $17.94 | 2024 | |
| Alfasigma USA, INC. | $17.17 | 2020 | |
| Currax Pharmaceuticals LLC | $14.53 | 2025 | Onzetra Xsail, Contrave |
| Sumitomo Pharma America, INC. | $14.14 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Sheidayi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.